Guide
Spravato (Esketamine) Billing: A Practical Guide for Behavioral Health Practices
How to bill Spravato (esketamine) correctly: G2082/G2083 vs. S0013, REMS, prior auth, and the two-hour monitoring that drives the claim.
Overview
Getting Paid for Spravato Without the Denials
Spravato (esketamine) can be a clinical breakthrough for treatment-resistant depression, but its billing is unlike anything else in a behavioral health practice. Between REMS certification, prior authorization, two-hour monitoring requirements, and payer-specific coding rules, a single missed step can turn a high-cost induction into a write-off. This guide breaks down how the coding actually works, where claims tend to fall apart, and what to confirm before your first patient ever sits down for monitoring. Reimbursement rules vary by payer and state, so treat the specifics below as a framework to verify, not a guarantee.
The Codes
Two Billing Models You Have to Choose Between
The biggest source of confusion is that there isn’t one universal way to bill Spravato. Most payers want a bundled HCPCS code that wraps the visit, the drug, and the monitoring into a single line. Others want the drug billed separately under a “buy-and-bill” model alongside a standard evaluation and management (E/M) code. The right answer is whatever each individual payer says it is, and using the wrong model is one of the fastest paths to a denial.
G2082 — Bundled, Lower Dose
An office or outpatient E/M visit plus the provision of up to 56 mg of esketamine and the required two hours of post-administration monitoring. This is the most common code for a standard induction or maintenance dose.
G2083 — Bundled, Higher Dose
The same bundled structure as G2082, but for doses greater than 56 mg. Choosing between G2082 and G2083 comes down to the milligrams actually administered that day, so accurate dose documentation drives the code.
S0013 + E/M — Buy-and-Bill
Some commercial payers reject the bundled G-codes and instead want the drug billed separately under S0013 (esketamine, 1 mg) plus a standard E/M code. Here the units matter: you report the exact milligrams as S0013 units.
Confirm Before You Induct
Never assume which model a payer uses. Call and verify the coding policy before the first induction so you bill it correctly from day one rather than reworking denied claims after the fact.
REMS
Why Monitoring and Certification Sit at the Center
Spravato is dispensed under a federal Risk Evaluation and Mitigation Strategy (REMS) program. The drug can only be administered in a certified healthcare setting, the patient must be monitored for at least two hours after each dose, and that monitoring has to be documented in the record. This isn’t just a clinical formality — the bundled G-codes are built around that two-hour monitoring window. If the monitoring time isn’t captured in your documentation, the clinical basis for the code you billed effectively disappears, and payers will treat the claim accordingly.
REMS certification is required to administer the drug, but it does not replace payer enrollment or prior authorization — those are separate steps, and skipping either one is a common reason induction claims get denied.
Because these requirements layer on top of standard behavioral health rules, many practices fold Spravato oversight into their broader revenue cycle management workflow rather than treating it as a one-off. The same discipline that keeps routine claims clean — eligibility checks, documentation standards, denial tracking — is exactly what a REMS-restricted, prior-auth-heavy therapy demands.
Get It Right
What to Lock Down Before the First Dose
Spravato almost always requires prior authorization in addition to REMS enrollment, so the work that protects your reimbursement happens well before the patient arrives. Treat the steps below as a pre-induction checklist, and document each one in the chart as you go.
- Obtain prior authorization for the specific patient, dose range, and number of sessions the payer will cover.
- Confirm the payer’s coding model — bundled G2082/G2083 versus S0013 plus a separate E/M — and record it in your billing notes.
- Verify your REMS-certified site is on file with the payer so the claim doesn’t bounce for an unrecognized administration location.
- Build a documentation template that captures dose administered and the full two-hour monitoring window for every visit.
- Reconcile drug units carefully — milligrams administered must match what you bill, whether that’s the G-code tier or S0013 units.
Denials
The Five Mistakes That Sink Spravato Claims
When a Spravato claim is denied, it usually traces back to a short list of preventable issues. Knowing them in advance lets you build controls into your front-end process instead of chasing appeals later.
PA Not Obtained
The most common denial. REMS enrollment is not prior authorization — if the payer’s PA wasn’t secured for this patient and course of treatment, the claim is at risk regardless of how clean the documentation is.
REMS Site Not on File
If the certified administration site isn’t registered with the payer, claims can be denied for an invalid location even when the care was delivered correctly. Verify the site is recognized before billing.
Monitoring Not Documented
The two-hour monitoring window is the backbone of the G-codes. If it isn’t clearly recorded, payers may deny or downgrade the claim because the documentation doesn’t support what was billed.
Wrong Model or Unit Errors
Billing the bundled G-codes when the payer wants S0013, or reporting the wrong drug units, leads to denials and rework. Match the model to the payer and reconcile milligrams every time.
In Practice
Building Spravato Into a Repeatable Workflow
The practices that get paid consistently for Spravato don’t reinvent the process for every patient. They maintain a payer-by-payer reference of coding models and PA requirements, use a standardized monitoring template, and track denials by reason so patterns surface early. Because the therapy lives at the intersection of pharmacy billing and behavioral health, it benefits from the same rigor as the rest of your psychiatry and behavioral health billing. If your team is already strong on mental health billing fundamentals, layering in Spravato’s REMS and authorization steps is far more about process discipline than reinventing the wheel. Rules shift over time and differ by plan and state, so revisit your payer reference periodically and verify before each new induction.
FAQ
Frequently asked questions
Do I bill G2082/G2083 or S0013 for Spravato?
It depends entirely on the payer. Most payers accept the bundled G-codes (G2082 for up to 56 mg, G2083 for more than 56 mg), which include the E/M visit, the drug, and two hours of monitoring. Some commercial payers instead require the drug billed separately under S0013 plus a standard E/M. Confirm each payer’s preferred model before the first induction.
Is REMS enrollment the same as prior authorization?
No. REMS certification allows your site to administer esketamine, but it does not authorize payment. Spravato almost always requires prior authorization in addition to REMS enrollment, and missing the PA is one of the most common reasons claims are denied.
Why do Spravato claims get denied so often?
The frequent culprits are prior authorization not being obtained, the REMS site not being on file with the payer, the two-hour monitoring time not being documented, using the wrong coding model for that payer, and drug-unit errors. Most are preventable with front-end verification and solid documentation.
What documentation does the monitoring requirement need?
Spravato’s REMS program requires at least two hours of post-administration monitoring in a certified healthcare setting, and that monitoring must be documented in the patient record. Because the G-codes are built around this window, capturing the dose and the full monitoring period for every visit is essential to support the claim.
Spravato billing doesn’t have to mean denials.
Let’s review your payer mix, REMS setup, and authorization workflow so your inductions get paid the first time.